{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_06",
        "affectedSection": "Section 1: Synopsis; Section 4.4: Duration of the Study",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Extension of Part B open-label duration from 1 year to 2 years following Last Patient Out from Part A."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_06",
        "affectedSection": "Section 1: Synopsis; Section 6.1.6; Section 10.10: Appendix J",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduction of home infusion facilities for patients in preselected countries."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_06",
        "affectedSection": "Section 3.2; Section 3.5; Section 4.3.8; Section 7.7",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Addition of new exploratory objectives and endpoints to evaluate the immunogenicity (ADA) of BIVV009."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_06",
        "affectedSection": "Section 1: Synopsis: Statistical Methods",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Replacement of Intent to Treat (ITT) terminology with Full Analysis Set (FAS)."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_06",
        "affectedSection": "Section 10.1: Appendix A",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Correction of clinical laboratory evaluation parameters."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_06",
        "reasonText": "Gather more evidence on long-term safety, tolerability and durability of response of BIVV009.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_06",
        "reasonText": "Evaluate the safety and patient satisfaction with the convenience of home infusion.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_06",
        "reasonText": "Help characterize immunogenicity of BIVV009.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_06",
        "reasonText": "Comply with Sanofi organizational standards.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_06",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1",
        "beforeText": "1 year following last patient out (LPO) under Part A",
        "afterText": "2 years instead of 1 year following last patient out (LPO) under Part A",
        "summary": "Extended Part B duration."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_06",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "3.5",
        "afterText": "Exploratory Objectives were added for Part B to describe the safety and patient satisfaction with the convenience of home infusion",
        "summary": "Added home infusion exploratory objectives."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_06",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Synopsis",
        "beforeText": "Intent to treat (ITT)",
        "afterText": "Full Analysis Set (FAS)",
        "summary": "Updated statistical terminology."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_06",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "10.1",
        "beforeText": "Iron",
        "summary": "Removed Iron from the clinical chemistry panel."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_06",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.1.1",
        "afterText": "Revaccination with booster doses should be given according to regional guidelines for patients with persistent complement deficiency",
        "summary": "Clarified vaccination requirements for encapsulated bacterial pathogens."
      },
      {
        "id": "change_6",
        "amendmentId": "amend_06",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.3",
        "afterText": "PD back-up samples collected at the following time points Day 7, 35, 77, 133 and 175, may be used to assay ADA",
        "summary": "Added use of back-up samples for ADA testing."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 6
    }
  }
}